Many institutions can train outstanding clinical oncologists, however, few institutions contain the necessary elements required to train these young clinicians for a career in investigation. San Antonio has a long history of boil basic and clinical cancer research and has developed major expertise in cooperative group trials, investigational drug development, breast cancer research, and bone marrow transplant. To obtain excellence in these areas, basic and clinical investigators have worked closely together. Recently, through the joint efforts of the University of Texas Health Science Center (UTHSCSA) and the Cancer Therapy and Research Center (CTRC), the cancer research efforts have been organized into San Antonio Cancer Institute (SACI), an NCI designated comprehensive cancer center. As described in this application, San Antonio can provide trainees with appropriate research experience, didactic instruction, and mentoring to begin a career in clinical cancer research. Our program will identify physician candidate trainees from medical, surgical, and radiation oncology. An Advisory Committee composed of key members of SACI and the clinical chairs of UTHSCSA will provide oversight for the training program. Trainees will be supported for two years on this training grant. Each trainee will select a SACI member as a mentor for their training in laboratory research skills. Once selected, Research Committee will be formed to provide detailed oversight of the trainee's progress. At the end of the first year of research support, the trainee will submit a clinical investigation proposal. The proposal will be designed to generate sufficient data to launch their research career. At the end of two years of support, th trainee will return to their clinical department as junior faculty members to continue their career development. Thus, this training program will allow young clinicians to develop an area of research expertise and bring this expertise back to their """"""""home"""""""" clinical department.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA001723-10
Application #
6375471
Study Section
Special Emphasis Panel (ZCA1-GRB-J (01))
Program Officer
Lei, Ming
Project Start
1992-09-05
Project End
2003-06-30
Budget Start
2001-09-18
Budget End
2003-06-30
Support Year
10
Fiscal Year
2001
Total Cost
$424,669
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kazhdan, I; Long, L; Montellano, R et al. (2006) Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther 13:141-9
Kazhdan, Irene; Marciniak, Robert A (2004) Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther 11:691-8
Wang, W; Waters, S J; MacDonald, J R et al. (2001) Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 21:1789-94
Raymond, E; Sun, D; Izbicka, E et al. (1999) A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. Br J Cancer 80:1332-41
Yang, L M; Tin-U, C; Wu, K et al. (1999) Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 4:377-88
Sharma, S; Raymond, E; Soda, H et al. (1998) Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line. Leuk Res 22:663-70
Sharma, J J; Razvillas, B; Stephens, C D et al. (1997) Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15:361-4
Sharma, S; Raymond, E; Soda, H et al. (1997) Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 8:1063-74
Alsina, M; Boyce, B; Devlin, R D et al. (1996) Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495-501
Alsina, M; Boyce, B F; Mundy, G R et al. (1995) An in vivo model of human multiple myeloma bone disease. Stem Cells 13 Suppl 2:48-50

Showing the most recent 10 out of 11 publications